Opdivo earned $840 million in second quarter sales (driven largely by sales in melanoma and NSCLC) well ahead of Keytruda’s $314 million, but this gap could narrow if more data emerges which ...

Shares of this biotech giant have lost 16.3% year to date compared with the industry’s decline of 2.7%. The stock has also ...

Opdivo is used in adults to treat various cancers, including non-small cell lung cancer, melanoma, and classic Hodgkin’s lymphoma.For treating melanoma and a type of colorectal cancer, Opdivo ...

Bristol Myers Squibb (NYSE:BMY) announced Saturday that its checkpoint inhibitors Opdivo and Yervoy, when combined, reduced ...

Image Source: Zacks Investment Research. More on BMY’s Opdivo plus Yervoy Combo for HCC. The positive CHMP opinion was based ...

U.S. Food and Drug Administration Approves Opdivo ® (nivolumab) plus Yervoy ® (ipilimumab) as a First-Line Treatment for Unresectable or Metastatic Hepatocellular Carcinoma. Based on the Phase 3 ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for some types of cancer in adults and certain children. As with other drugs, Opdivo can cause side effects, such as joint pain and fatigue.

Opdivo, which is used to treat certain types of cancer, can cause side effects such as confusion. Learn about Opdivo’s side effects and how to manage them.

Opdivo’s U.S. patent loss is expected in 2028, Europe in 2030, and Japan in 2031. Another cancer drug, Yervoy (ipilimumab), is expected to lose market exclusivity in 2025 in the U.S. and Japan ...

Opdivo (nivolumab) and Opdivo Qvantig (nivolumab/hyaluronidase-nvhy) are a type of cancer treatment called immunotherapy. Immunotherapy works by using the body's immune system to fight cancer ...

Opdivo (nivolumab) is a brand-name IV infusion prescribed for non-small cell lung cancer (NSCLC) in some situations. This article covers topics such as side effects, dosage, and how Opdivo works.